Patrick J. Cocke

Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor

James E Audia, R. Dean, T. Lindstrom, 2011, The Journal of Neuroscience.

Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species

R. Dean, D. McKinzie, L. L. Winneroski, 2022, Journal of Alzheimer's disease reports.

The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans

R. Dean, T. Lindstrom, D. Timm, 2015, The Journal of Neuroscience.

Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.

D. McKinzie, D. Timm, L. L. Winneroski, 2021, Journal of medicinal chemistry.

P1-017: Comparison of cisternal and lumbar cerebrospinal fluid amyloid-beta concentrations following oral administration of LY450139 dihydrate to Beagle dogs

P. May, D. Ness, L. Boggs, 2008, Alzheimer's & Dementia.